A long-term extension trial of 389 patients found Attruby significantly cut death risk in transthyretin amyloid ...
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results